Diisocyanates

Diisocyanates Antitrust Litigation alleges that manufacturers of diisocyanate chemicals — key inputs used in producing polyurethane foam and other industrial materials — coordinated on pricing sold to direct and indirect purchasers across the chemical manufacturing supply chain. Centralized in the Western District of Pennsylvania in 2018, the docket carries 12 pending actions after roughly seven years of litigation, a claim population that reflects a mature matter well into its later procedural stages.

For a funder, this docket's age and comparatively small remaining action count suggest that much of the original claim population has already worked through class-certification and, in many instances, settlement, leaving a narrower set of remaining disputes. Diligence should focus on why these specific claims remain unresolved — whether they represent opt-outs, later-filed actions, or claims with more contested facts than the bulk of the original docket.

Chemical manufacturers, foam producers, and other industrial purchasers of diisocyanates with documented purchase volumes are the relevant claimant pool for commercial claim funding under Criterica Capital's commercial litigation finance line — not a medical-lien matter. Single-matter or small-group underwriting is the more realistic structure given how narrow the remaining claim population is at this stage. A structure and litigation brief on the current claim population is also available.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.